Market cap
$6.0M

Alzamend Neuro Inc. (ALZN) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 1 wire item for ALZN, including 1 SEC filing. The most recent was published Nov 10, 2026.

Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.

Financial highlights

Full financials
Net income, TTM
-$9.10M
Cash
$7.59M

For the twelve months ended Jul 31, 2026, from SEC filings. Not investment advice.

News · 26 weeks28-50%
2026-05-24: 02026-05-31: 02026-06-07: 02026-06-14: 02026-06-21: 02026-06-28: 02026-07-05: 02026-07-12: 02026-07-19: 22026-07-26: 02026-08-02: 122026-08-09: 02026-08-16: 52026-08-23: 12026-08-30: 32026-09-06: 12026-09-13: 12026-09-20: 02026-09-27: 12026-10-04: 12026-10-11: 02026-10-18: 02026-10-25: 02026-11-01: 02026-11-08: 12026-11-15: 0
2026-05-242026-11-15
Mix1490d
  • Insider5(36%)
  • SEC Filings5(36%)
  • Other4(29%)
Activity · 52 weeks4328 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news

Latest news

25 items

ALZN FAQ

10 questions
  • What does Alzamend Neuro Inc. do?
    Alzamend Neuro, Inc., a preclinical stage biopharmaceutical company, focuses on developing products for the treatment of neurodegenerative diseases and psychiatric disorders. The company's lead product candidate is AL001 for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders. It is also developing AL002, a cell-based therapeutic vaccine, which seeks to restore the ability of the patient's immunological system to Alzheimer's. The company was incorporated in 2016 and is headquartered in Tampa, Florida.
  • What is the latest news on ALZN?
    In the last 30 days Quantisnow tracked 1 wire item for ALZN: 1 SEC filing. The most recent was published on November 10, 2026.
  • Is ALZN profitable?
    No. Alzamend Neuro Inc. reported a net loss of $9.10M for the twelve months ended Jul 31, 2026.
  • How much cash and debt does ALZN have?
    Alzamend Neuro Inc. reported $7.59M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • Where does ALZN stock trade?
    Alzamend Neuro Inc. (ALZN) is listed on NASDAQ.
  • What sector and industry is ALZN in?
    Alzamend Neuro Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
  • When did Alzamend Neuro Inc. go public?
    Alzamend Neuro Inc. (ALZN) completed its IPO in 2021.
  • What are analysts saying about ALZN?
    Alzamend Neuro Inc. has had 1 recent analyst action on file. The most recent action was from Ascendiant Capital Markets: Buy with a $8.00 price target on 2021-10-01. Recent price targets cluster around $8.00.
  • What companies are similar to ALZN?
    Notable peers in the same industry include ANVS (Annovis Bio Inc.), PRTA (Prothena Corporation plc), ABOS (Acumen Pharmaceuticals Inc.), CGTX (Cognition Therapeutics Inc.), AVXL (Anavex Life Sciences Corp.). Compare ALZN side-by-side with any of them on Quantisnow.
  • How can I track ALZN on Quantisnow?
    Quantisnow aggregates Alzamend Neuro Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALZN to receive live email and push alerts on every new disclosure.